New combo therapy shows promise for Hard-to-Treat cancers

NCT ID NCT01968109

Completed Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

First seen Jan 09, 2026 · Last updated May 31, 2026 · Updated 26 times

Summary

This study tested an experimental drug called BMS-986016 (anti-LAG-3) alone or combined with nivolumab in people with advanced solid tumors that had spread or couldn't be removed by surgery. It included several cancer types like lung, stomach, liver, kidney, bladder, head and neck, and melanoma. The main goals were to check safety and see if the treatment could shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Local Institution - 0001

Boston, Massachusetts, 02215, United States
Local Institution - 0002

Portland, Oregon, 97213, United States
Local Institution - 0003

Chicago, Illinois, 60637, United States
Local Institution - 0004

Baltimore, Maryland, 21287, United States
Local Institution - 0005

New York, New York, 10065, United States
Local Institution - 0006

Pamplona, 31008, Spain
Local Institution - 0007

Essen, 45122, Germany
Local Institution - 0008

Seattle, Washington, 98109, United States
Local Institution - 0010

Pittsburgh, Pennsylvania, 15232-1305, United States
Local Institution - 0011

Detroit, Michigan, 48201, United States
Local Institution - 0013

Naples, 80131, Italy
Local Institution - 0014

Milan, 20141, Italy
Local Institution - 0015

Barcelona, 08035, Spain
Local Institution - 0016

Zurich, 8091, Switzerland
Local Institution - 0017

Lausanne, 1011, Switzerland
Local Institution - 0018

Villejuif, 94800, France
Local Institution - 0019

Oslo, 0379, Norway
Local Institution - 0020

Herlev, 2730, Denmark
Local Institution - 0021

Helsinki, Uusimaa, 00290, Finland
Local Institution - 0022

London, Greater London, SW3 6JJ, United Kingdom
Local Institution - 0023

Vienna, 1090, Austria
Local Institution - 0024

Vienna, 1090, Austria
Local Institution - 0025

Amsterdam, North Holland, 1066 CX, Netherlands
Local Institution - 0026

Toulouse, 31059, France
Local Institution - 0027

London, Greater London, NW1 2PG, United Kingdom
Local Institution - 0028

Copenhagen, 2100, Denmark
Local Institution - 0029

North Sydney, New South Wales, 2060, Australia
Local Institution - 0031

Brisbane, Queensland, 4120, Australia
Local Institution - 0032

Nedlands, Western Australia, 6009, Australia
Local Institution - 0033

Melbourne, Victoria, 3000, Australia
Local Institution - 0034

Manchester, M20 4BX, United Kingdom
Local Institution - 0035

Padova, 35128, Italy
Local Institution - 0036

Pierre-Bénite, 69495, France
Local Institution - 0037

Nantes, 44093, France
Local Institution - 0038

Marseille, 13385, France
Local Institution - 0039

Southport, Queensland, 4215, Australia
Local Institution - 0040

Heilbronn, 74078, Germany
Local Institution - 0041

Würzburg, 97080, Germany
Local Institution - 0043

La Jolla, California, 92093-0698, United States
Local Institution - 0044

St Louis, Missouri, 63110, United States
Local Institution - 0045

Houston, Texas, 77030, United States
Local Institution - 0046

Málaga, 29010, Spain
Local Institution - 0047

Allentown, Pennsylvania, 18103, United States
Local Institution - 0048

Niles, Illinois, 60714, United States
Local Institution - 0049

Toronto, Ontario, M5G 2M9, Canada
Local Institution - 0050

Québec, Quebec, G1J 1Z4, Canada
Local Institution - 0051

Rochester, Minnesota, 55905-0001, United States
Local Institution - 0052

Chuo-ku, Tokyo, 1040045, Japan
Local Institution - 0053

Aurora, Colorado, 80045, United States
Local Institution - 0054

Sunto-gun, Shizuoka, 4118777, Japan
Local Institution - 0055

Nagoya, Aichi-ken, 4668560, Japan
Local Institution - 0057

Dallas, Texas, 75246, United States
Local Institution - 0058

Tampa, Florida, 33612, United States
Local Institution - 0059

Sapporo, Hokkaido, 0608543, Japan

Conditions

Explore the condition pages connected to this study.

NEOPLASMS BY SITE NEOPLASMS BY SITE

Conditions inferred from the trial description

These were inferred from the trial's summary, not listed by the trial registrant.

BLADDER CANCER GASTRIC CANCER HEPATOCELLULAR CARCINOMA MELANOMA NON SMALL CELL LUNG CANCER RENAL CELL CARCINOMA SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK